LOW-INTENSITY ORAL ANTICOAGULATION IN SICKLE-CELL DISEASE REVERSES THE PRETHROMBOTIC STATE - PROMISES FOR TREATMENT

被引：44

作者：

WOLTERS, HJ

TENCATE, H

THOMAS, LLM

BRANDJES, DPM

VANDERENDE, A

VANDERHEIDEN, Y

VANEPS, LWS

机构：

[1] SLOTERVAART MUNICIPAL HOSP,DEPT CLIN CHEM,1066 EC AMSTERDAM,NETHERLANDS

[2] ACAD MED CTR,CTR THROMBOSIS HAEMOSTASIS ATHEROSCLEROSIS & INFL,AMSTERDAM,NETHERLANDS

[3] FREE UNIV AMSTERDAM,FAC MED,DEPT HAEMATOL,AMSTERDAM,NETHERLANDS

[4] DEPT GEOG PATHOL,AMSTERDAM,NETHERLANDS

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1995年 / 90卷 / 03期

关键词：

SICKLE-CELL DISEASE; ORAL ANTICOAGULANTS; HYPERCOAGULABILITY; THROMBIN PRODUCTION;

D O I：

10.1111/j.1365-2141.1995.tb05607.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Increased plasma levels of prothrombin fragment 1 + 2 (F1 + 2) found in patients with sickle-cell disease reflect enhanced endogenous thrombin generation, We postulate that hypercoagulability contributes to vaso-occlusion. The intensity of acenocoumarol treatment required to reduce the F1 + 2 level to 50% of pretreatment level was investigated in seven patients with symptomatic sickle-cell anaemia during steady-state disease for a period of 2 months, All patients had increased levels of F1 + 2 compared with an age-matched control group. Normalization of the F1 + 2 was achieved at a median INR of 1 . 64 (range 1 . 18-2 . 2). it is concluded that low-intensity oral anticoagulation normalizes the hypercoagulability in sickle-cell disease.

引用

页码：715 / 717

页数：3

共 10 条

[1]

The effect of low‐dose warfarin on the risk of stroke in patients with non‐rheumatic atrial fibrillation, New England Journal of Medicine, 323, pp. 1505-1511, (1990)

[2]

Chiu D., Lubin B., Roelofsen B., Van Deenen L.L.M., Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry, Blood, 58, pp. 398-401, (1981)

[3]

Conway E.M., Bauer K.A., Barzegar S., Rosenberg R.D., Suppression of hemostatic system activation by oral anticoagulants in the blood of patients with thrombotic diatheses, Journal of Clinical Investigation, 80, pp. 1535-1544, (1987)

[4]

Francis R.B., Johnson C.S., Vascular occlusion in sickle cell disease: current concepts and unanswered questions, Blood, 77, pp. 1405-1514, (1991)

[5]

Kurantsin-Mills J., Ofosu F.A., Safa T.K., Siegel R.S., Lessin L.S., Plasma factor VII and thrombin‐antithrombin III levels indicate increased tissue factor activity in sickle‐cell patients, British Journal of Haematology, 81, pp. 539-544, (1992)

[6]

Millenson M.M., Bauer K.A., Kistler J.P., Barzegar S., Tulin L., Rosenberg R.D., Monitoring “mini‐intensity” anticoagulation with warfarin: comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment Fl + 2 levels, Blood, 79, pp. 2034-2038, (1992)

[7]

Peters M., Plaat B.E.C., ten Cate H., Wolters H.J., Weening R.S., Brandjes D.P.M., Enhanced thrombin generation in children with sickle cell disease, Thrombosis and Hemostasis, 71, pp. 169-172, (1994)

[8]

Plat O.S., Brambilla D.J., Rosse W.F., Milner P.F., Castro O., Steinberg M.H., Mortality in sickle cell disease: life expectancy and risk factors for early death, New England Journal of Medicine, 330, pp. 1639-1644, (1994)

[9]

Salvaggio J.E., Arnold C.A., Banov C.H., Long‐term anticoagulation in sickle cell disease: a clinical study, New England Journal of Medicine, 269, pp. 182-186, (1963)

[10]

Turpie A.G.G., Hirsh J., Gunstensen J., Nelson H., Gent M., Randomised comparison of two intensities of oral anticoagulant therapy after tissue valve replacement, Lancet, 1, pp. 175-179, (1989)

← 1 →